Perform Another (Advanced) Search

1.  Newly Approved Drug Therapies (176) Azulfidine EN-tabs Tablets (sulfasalazine delayed release tablets, USP), Pharmacia & Upjohn,
...Newly Approved Drug Therapies (176) Azulfidine EN-tabs Tablets (sulfasalazine delayed release tablets, USP), Pharmacia & Upjohn, Drug Information The following information is obtained from various ...
...newswires, published medical journal articles, and medical conference presentations. Drug Name: Azulfidine EN-tabs Tablets (sulfasalazine delayed release tablets, USP) Company: Pharmacia & Upjohn Approval Status: Approved October 1996 Treatment Area: rheumatoid ...
View Page

2.  Study Posting (264) Trial #45050, Psoriasis and Psoriatic Disorders, Philadelphia, PA
...adequately responding to topical treatment • Signed informed consent form • No treatment UV radiation, etretinate, methotrexate, sulfasalazine, cyclosporine for 4 weeks • No topical treatment for 2 weeks • Prior treatment with anti CD4 ...
View Page

3.  Study Posting (2934) Trial #143165, Crohn's Disease, Boca Raton, FL
...following you may remain on the medication for the duration of the study: 5-ASA, sulfasalazine, steroids (30 mg or less), antibiotics • Diagnosed at least 3 months. Patient Exclusion Criteria • Diagnosed ...
View Page

4.  Study Posting (2205) Trial #151247, Ulcerative Colitis, Chicago, IL
...dose of any of the following medications for the specified amount of time: Mesalamine or Sulfasalazine for at least 6 weeks; Remicaid for at least 10 weeks; Imuran or Mercaptopurine at ...
View Page

5.  CenterWatch: New Medical Therapies in Disease Category (132), Rheumatoid Arthritis
...randomized, double-blinded, active treatment-controlled trial enrolled 121 subjects who received PMI-001 or Sulfasalazine for six months. The primary endpoint was the proportion of PMI-001 subjects who achieved ...
...Rheumatology (ACR20) response at the end of the trial in comparison to the proportion of sulfasalazine-treated subjects. By the trial’s conclusion, 53.3% of subjects in the PMI-001 ...
View Page

6.  Study Posting (455) Trial #117567, Ulcerative Colitis, Wheat Ridge, CO
...inadequate response to one or more of the following treatments: • Oral aminosalicylates (e.g. mesalamine, sulfasalazine, olsalazine, balsalizide) at or above the approved label dose for induction therapy for at least ...
...OR • Currently receiving one or more of the following treatments: • Oral aminosalicylates (e.g. mesalamine, sulfasalazine, olsalazine, balsalizide) at or above the approved label dose for at least 6 weeks and ...
View Page

7.  CenterWatch: List of Newly Approved Drug Thearapies
...Treatment for advanced breast cancer in postmenopausal women, Approved January 1996 Azulfidine EN-tabs Tablets (sulfasalazine delayed release tablets, USP) ; Pharmacia & Upjohn; Treatment for rheumatoid arthritis, Approved October 1996 Campostar ; Pharmacia ...
...sodium) ; Wyeth; Treatment for hospital-acquired pneumonia, Approved May 1996 Rheumatology Azulfidine EN-tabs Tablets (sulfasalazine delayed release tablets, USP) ; Pharmacia & Upjohn; Treatment for rheumatoid arthritis, Approved October 1996 Lodine (etodolac ...
View Page

8.  Study Posting (709) Trial #109114, Skin Infections/Disorders, Stanford, CA
...Previous exposure to alefacept or efalizumab within 6 weeks of administration of study drug • Concurrent sulfasalazine therapy • Prior or concurrent cyclophosphamide therapy • Active severe infections (see warning and contraindications in etanercept ...
View Page

9.  Study Posting (4383) Trial #151320, Psoriasis and Psoriatic Disorders, Dallas, TX
...Anthralin • Any other systemic psoriasis therapy (eg, methotrexate, cyclosporine), including oral or parenteral corticosteroids • Cyclophosphamide • Sulfasalazine • Anakinra Product: Etanercept Protocol Number: 20080014 Date: 19 August 2008 Page 18 of 60 • Use ...
View Page

10.  CenterWatch: Rheumatology Approved Drug Therapies
...Pharmaceutical; Treatment for arthritis, Approved March 1997 Drugs Approved in 1996 Azulfidine EN-tabs Tablets (sulfasalazine delayed release tablets, USP) ; Pharmacia & Upjohn; Treatment for rheumatoid arthritis, Approved October 1996 Lodine (etodolac ...
View Page

11.  Study Posting (5339) Trial #156637, Arthritis and Arthritic Pain (Pediatric), Bronx, NY
...Treatment with other disease modifying anti-rheumatic drug (DMARD) including but not limited to azathioprine, sulfasalazine, cyclosporine, tacrolimus, tocilizumab and thalidomide within 4 weeks or rituximab for 6 months or cyclophosphomide ...
View Page

12.  Study Posting (455) Trial #128298, Crohn's Disease, Wheat Ridge, CO
...controlled • Must currently be receiving treatment with one of the following: • Oral 5-ASA or sulfasalazine at a stable dose for at least 3 weeks • Oral corticosteroids (prednisolone 40 mg or ...
View Page

13.  CenterWatch: New Medical Therapies in Disease Category (152), Ulcerative Colitis
...placebo for eight weeks. Subjects were also permitted the use of 5-ASA products or sulfasalazine. The primary efficacy endpoint was the proportion of subjects showing a three-point reduction in ...
View Page

14.  CenterWatch: New Medical Therapies in Disease Category (51), Crohn's Disease
...placebo for eight weeks. Subjects were also permitted the use of 5-ASA products or sulfasalazine. The primary efficacy endpoint was the proportion of subjects showing a three-point reduction in ...
View Page

15.  CenterWatch: Endocrinology Approved Drug Therapies
...Treatment for advanced breast cancer in postmenopausal women, Approved January 1996 Azulfidine EN-tabs Tablets (sulfasalazine delayed release tablets, USP) ; Pharmacia & Upjohn; Treatment for rheumatoid arthritis, Approved October 1996 Campostar ; Pharmacia ...
View Page

16. CWW0914_040405
...this hydroxamic acid derivative include inhibiting the expression of B1 kinin receptors and histone deacetylase. Sulfasalazine, which also reduces synthesis of inflammatory mediators and inflammatory cytokines, is a derivative of 5 ...
...Laurie Barclay, M.D. CenterWatch 19 Grant Opportunities Drug Company Contact Additional Information Phase I Sulfasalazine Pfizer (212) 733-2323 a 5-ASA derivative; reduces the synthesis of www.pfizer.com ...
View Page